CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases

被引：217

作者：

Zhang, Jing ^{[1
]}

Sokal, Izabela ^{[1
]}

Peskind, Elaine R. ^{[2
,3
]}

Quinn, Joseph F. ^{[4
]}

Jankovic, Joseph ^{[5
,6
]}

Kenney, Christopher ^{[5
,6
]}

Chung, Kathryn A. ^{[4
]}

Millard, Steven P. ^{[3
]}

Nutt, John G. ^{[4
]}

Montine, Thomas J. ^{[1
]}

机构：

[1] Univ Washington, Harborview Med Ctr, Dept Pathol, Sch Med, Seattle, WA 98104 USA

[2] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA

[3] Vet Affairs Puget Sound Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Seattle, WA USA

[4] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA

[5] Baylor Coll Med, Dept Neurol, Parkinsons Dis Ctr, Houston, TX 77030 USA

[6] Baylor Coll Med, Dept Neurol, Movement Disorders Clin, Houston, TX 77030 USA

来源：

AMERICAN JOURNAL OF CLINICAL PATHOLOGY | 2008年 / 129卷 / 04期

关键词：

cerebrospinal fluid; Alzheimer disease; Parkinson disease; biomarkers; analyte profile; random forest algorithm;

D O I：

10.1309/W01Y0B808EMEH12L

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

The therapeutic imperative for Alzheimer disease (AD) and Parkinson disease (PD) calls for discovery and validation of biomarkers. Increased cerebrospinal fluid (CSF) tau and decreased amyloid (A) beta(42) have been validated as biomarkers of AD. In contrast, there is no validated CSF biomarker for PD. We validated our proteomics-discovered multianalyte profile (MAP) in CSF from 95 control subjects, 48 patients with probable AD, and 40 patients with probable PD. An optimal 8-member MAP agreed with expert diagnosis for 90 control subjects (95%), 36 patients with probable AD (75%), and 38 patients with probable PD (95%). This MAP consisted of the following (in decreasing order of contribution): tau, brain-derived neurotrophic factor, interleukin 8, A beta(42), beta(2)-microglobulin, vitamin D binding protein, apolipoprotein (apo) AII, and apoE. This first large-scale validation of a proteomic-discovered MAP suggests a panel of 8 CSF proteins that are highly effective at identifying PD and moderately effective at identifying AD.

引用

页码：526 / 529

页数：4

共 17 条

[1]

Abdi F, 2006, J ALZHEIMERS DIS, V9, P293

[2] Random forests [J].

Breiman, L .

MACHINE LEARNING, 2001, 45 (01) :5-32

[3] Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects [J].

Castaño, EM ;

Roher, AE ;

Esh, CL ;

Kokjohn, TA ;

Beach, T .

NEUROLOGICAL RESEARCH, 2006, 28 (02) :155-163

[4] Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients [J].

Davidsson, P ;

Westman-Brinkmalm, A ;

Nilsson, CL ;

Lindbjer, M ;

Paulson, L ;

Andreasen, N ;

Sjögren, M ;

Blennow, K .

NEUROREPORT, 2002, 13 (05) :611-615

[5] Gene selection and classification of microarray data using random forest -: art. no. 3 [J].

Díaz-Uriarte, R ;

de Andrés, SA .

BMC BIOINFORMATICS, 2006, 7 (1)

[6] Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease [J].

Finehout, Erin J. ;

Franck, Zsofia ;

Choe, Leila H. ;

Relkin, Norman ;

Lee, Kelvin H. .

ANNALS OF NEUROLOGY, 2007, 61 (02) :120-129

[7]

Galasko D, 2005, J ALZHEIMERS DIS, V8, P339

[8] Diagnostic criteria for Parkinson disease [J].

Gelb, DJ ;

Oliver, E ;

Gilman, S .

ARCHIVES OF NEUROLOGY, 1999, 56 (01) :33-39

[9] Movement disorder society task force report on the Hoehn and Yahr staging scale: Status and recommendations [J].

Goetz, CG ;

Poewe, W ;

Rascol, O ;

Sampaio, C ;

Stebbins, GT ;

Counsell, C ;

Giladi, N ;

Holloway, RG ;

Moore, CG ;

Wenning, GK ;

Yahr, MD ;

Seidl, L .

MOVEMENT DISORDERS, 2004, 19 (09) :1020-1028

[10]

MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939

← 1 2 →